Hypofractionated Radiotherapy in Breast Cancer Patients With Prosthetic Reconstruction

Not Applicable

Recruiting

• Conditions: Breast Cancer
• Interventions: Radiation: Hypofractionation

• Registration Number: NCT05491395
• Lead Sponsor: Barretos Cancer Hospital

Brief Summary

RATIONALE:

Radiotherapy (RT) can be indicated to patients submitted to breast-conserving surgery, but, despite the benefits, adjuvant RT can cause contracture generated by tissue fibrosis in patients with immediate prosthetic reconstruction, which could cause prosthesis loss. The biological explanation of this outcome is not fully understood, but recent advances in the analysis of patient-derived blood can contribute to establishing a connection of molecular alterations related to this clinical outcome.

There is not a consensus about using hypofractionated RT schemes for patients with BCS and breast reconstruction since no studies had investigated the reasons why some patients lose the prosthesis.

PURPOSE: This study will evaluate G3 toxicity rate in breast cancer patients with immediate prosthetic reconstruction, submitted to hypofractionated radiotherapy, analyzing capsular contracture, leakage, infection, and bad positioning in order to demonstrate the noninferiority of Hypo-RT with the conventional RT. Additionally, the molecular profile of blood samples will be investigated in order to find biomarkers related to inflammations processes and response to treatment.

Detailed Description

General aim: To evaluated if hypofractionated accelerated radiotherapy in patients with breast cancer undergoing immediate breast implant reconstruction surgery is non inferior to conventional radiotherapy.

Aim 1 (Primary objective): Assess the G3 toxicity rate - loss of the prosthesis (complication that requires surgical intervention: capsular contracture, leakage, infection, malpositioning).

Aim 2 (Specific secondary objectives):

* Compare local recurrence rate between two groups;

* Compare quality of life index between two groups using EORTC QLQ-C30 / EORTC QLQ-BR45 scales during treatment, after 6 and 12 months after treatment ending;

* Compare self-image differences between groups;

* Compare acute and late radiodermatitis rates by CTCAE 4.0;

* Analyse dosimetric planning differences considering the volumes of all breast and breast without prosthesis;

* Study inflammation molecular markers, which may indicate an increased risk of fibrosis;

* Evaluate the change in the profile of extracellular vesicles in patients treated with RT hypofractionated and conventional;

* Evaluate the change in EV collagen production after in vitro irradiation, using co-culture experiments with breast cells and fibroblasts.

Study Timeline

• Status Verified: 2022-06
• Study First Submitted: 2022-06-13
• Study Start: 2022-06-27
• Study First Submitted QC: 2022-08-04
• Last Update Submitted: 2022-08-04
• Study First Posted: 2022-08-08
• Last Update Posted: 2022-08-08
• Primary Completion: 2026-05-01
• Study Completion: 2029-05-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 120

Inclusion Criteria

• Women with confirmed histological diagnosis of invasive ductal carcinoma and lobular breast carcinoma;
• Radical mastectomy with immediate reconstruction with a prosthesis;
• Patients indicated for adjuvant RT;
• Any lymph node status;
• With or without adjuvant chemotherapy;
• ECOG performance status from 0-2;
• > 18 years old;
• Informed Consent Form applied before any study-specific procedure.

Exclusion Criteria

• Another histological diagnosis than invasive ductal carcinoma or lobular carcinoma;
• Previous history of neoplasm and/or radiotherapy and/ or quimiotherapy before this study;
• Distant metastatic disease;
• Palliative treatment;
• Patients with scleroderma / systemic lupus erythematosus.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Post Mastectomy Hypofractionated Radiotherapy Arm	Hypofractionation	Post Mastectomy Hypofractionated Radiotherapy Arm

Primary Outcome Measures

Name	Time	Method
Assess the G3 toxicity rate	2 years	loss of the prosthesis (complication that requires surgical intervention: capsular contracture, leakage, infection, malpositioning)

Secondary Outcome Measures

Name	Time	Method
Evaluate extracellular vesicles molecular profile	4 years	Evaluate the change in EV collagen production after in vitro irradiation, using co-culture experiments with breast cells and fibroblasts
Comparison of self-image using the EORTC Questionnaires European Organization for Research and Treatment of Cancer, where a high or low score may suggest good quality of life depending on the domain of the questionnaire	5 years	Compare self-image differences between groups
Inflammation markers screening - detection of cytokines with the CBA panel	3 years	Study inflammation molecular markers, which may indicate an increased risk of fibrosis. The cytokines present in the plasma will be evaluated using the Cytometric Beads Array technique with the CBA panel - Human Th1/Th2/Th17CBAKit which, through beads, is able to identify the expression of cytokines expressed by Th1, Th2 standard lymphocytes and Th17, including IL-2, IL-4, IL-6, IL-10, IL-17A, TNF e IFN-γ. After proper labeling, the immunophenotypic analyzes will be performed in a BD FAC Symphony flow cytometer.
Assessment of quality of life through the EORTC Questionnaires European Organization for Research and Treatment of Cancer, where a high or low score may suggest good quality of life depending on the domain of the questionnaire	2 years	Compare quality of life index between two groups using EORTC scales during treatment, after 6 and 12 months after treatment ending
Dosimetric analysis	5 years	Analyze dosimetric planning differences considering the volumes of all breast and breast without prosthesis
Local recurrence	5 years	Compare local recurrence rate between two groups
Extracellular vesicles isolation and characterization	4 years	Evaluate the change in the profile of extracellular vesicles in patients treated with RT hypofractionated and conventional
Compare acute and late radiodermatitis rates by Common Terminology Criteria for Adverse Events (CTCAE) 4.0	2 years	Acute and late radiodermatitis rateswill be evaluated by CTCAE 4.0 scale, using the adverse event (AE) reporting. A grading (severity) scale is provided for each AE term.

Trial Locations

Locations (1)

Radiation Oncology Department; 🇧🇷 Barretos, São Paulo, Brazil